25
Participants
Start Date
May 30, 2018
Primary Completion Date
May 31, 2021
Study Completion Date
June 1, 2021
Phonak Audeo B-R 90 hearing aid device (Active)
Hearing aids will be the latest Audeo B-R 90 devices manufactured by Phonak. Full amplification hearing aids will have their gain determined by audiometric profile as per standard clinical practice
Duloxetine or escitalopram
We opted to allow two potential medication choices so that study participation could be offered to individuals who had previously taken one medication and either not responded or not tolerated it. After 4 weeks if subjects do not meet remission criteria (HRSD≤10), the dose of study medication will be increased to escitalopram 20mg or duloxetine 60mg for the remaining 8 weeks of the study.
Audeo B-R 90 hearing aid device (Sham)
Hearing aids will be the latest Audeo B-R 90 devices manufactured by Phonak. Low amplification hearing aids will be programmed to a hearing threshold of 10dB across all frequencies
New York State Psychiatric Institute, New York
National Institute on Aging (NIA)
NIH
New York State Psychiatric Institute
OTHER